Lantheus (LNTH) Lowered to Hold at BidaskClub

Lantheus (NASDAQ:LNTH) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a report released on Thursday.

Other research analysts have also issued reports about the company. Zacks Investment Research raised Lantheus from a “hold” rating to a “buy” rating and set a $27.00 price target for the company in a research report on Saturday, January 27th. ValuEngine lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Credit Suisse Group boosted their price target on Lantheus from $19.00 to $23.00 and gave the stock a “neutral” rating in a research report on Friday, November 3rd. Finally, Jefferies Group reissued a “buy” rating and issued a $22.00 price target on shares of Lantheus in a research report on Thursday, October 12th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $24.75.

Lantheus (LNTH) opened at $20.15 on Thursday. The company has a market capitalization of $755.75 and a price-to-earnings ratio of 25.19. The company has a debt-to-equity ratio of -3.41, a current ratio of 2.96 and a quick ratio of 2.46. Lantheus has a 1 year low of $8.85 and a 1 year high of $24.45.

In related news, insider Michael P. Duffy sold 11,917 shares of the business’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $21.63, for a total transaction of $257,764.71. Following the transaction, the insider now directly owns 152,301 shares in the company, valued at approximately $3,294,270.63. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO John W. Crowley sold 3,866 shares of the business’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $23.52, for a total value of $90,928.32. The disclosure for this sale can be found here. Over the last three months, insiders sold 48,752 shares of company stock valued at $1,077,129. Corporate insiders own 2.30% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System grew its stake in Lantheus by 5.2% during the 3rd quarter. California State Teachers Retirement System now owns 48,609 shares of the medical equipment provider’s stock worth $865,000 after buying an additional 2,409 shares during the last quarter. Rhumbline Advisers grew its stake in Lantheus by 5.0% during the 3rd quarter. Rhumbline Advisers now owns 53,702 shares of the medical equipment provider’s stock worth $956,000 after buying an additional 2,560 shares during the last quarter. New York State Teachers Retirement System grew its stake in Lantheus by 13.4% during the 3rd quarter. New York State Teachers Retirement System now owns 23,713 shares of the medical equipment provider’s stock worth $422,000 after buying an additional 2,800 shares during the last quarter. LS Investment Advisors LLC grew its stake in Lantheus by 47.1% during the 3rd quarter. LS Investment Advisors LLC now owns 9,306 shares of the medical equipment provider’s stock valued at $166,000 after purchasing an additional 2,981 shares during the last quarter. Finally, Cubist Systematic Strategies LLC grew its stake in Lantheus by 22.4% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 21,915 shares of the medical equipment provider’s stock valued at $390,000 after purchasing an additional 4,015 shares during the last quarter. Hedge funds and other institutional investors own 91.07% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Lantheus (LNTH) Lowered to Hold at BidaskClub” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://sportsperspectives.com/2018/02/08/lantheus-lnth-lowered-to-hold-at-bidaskclub.html.

Lantheus Company Profile

Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply